15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau-Reference-Cited by-同舟云学术

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

Published:2016-07-05 Issue:3 Volume:175 Page:410-418
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Eskelund Christian W.¹,Kolstad Arne²,Jerkeman Mats³,Räty Riikka⁴,Laurell Anna⁵,Eloranta Sandra⁶,Smedby Karin E.⁶,Husby Simon¹,Pedersen Lone B.¹,Andersen Niels S.¹,Eriksson Mikael³,Kimby Eva⁷,Bentzen Hans⁸,Kuittinen Outi⁹,Lauritzsen Grete F.²,Nilsson-Ehle Herman¹⁰,Ralfkiaer Elisabeth¹,Ehinger Mats¹¹,Sundström Christer¹²,Delabie Jan¹³,Karjalainen-Lindsberg Marja-Liisa¹⁴,Workman Christopher T.¹⁵¹⁶,Garde Christian¹⁵¹⁶,Elonen Erkki⁴,Brown Peter¹,Grønbaek Kirsten¹,Geisler Christian H.¹

Affiliation:

1. Department of Haematology; Rigshospitalet; Copenhagen Denmark

2. Department of Oncology; Oslo University Hospital; Oslo Norway

3. Department of Oncology; Lund University Hospital; Lund Sweden

4. Department of Haematology; Helsinki University Central Hospital; Helsinki Finland

5. Department of Oncology; Uppsala University Hospital; Uppsala Sweden

6. Clinical Epidemiology Unit; Department of Medicine Solna; Karolinska Institute; Stockholm Sweden

7. Department of Haematology; Karolinska Institute; Stockholm Sweden

8. Department of Haematology; Aarhus University Hospital; Aarhus Denmark

9. Department of Oncology and Radiotherapy; Oulu University Hospital; Oulu Finland

10. Section of Haematology and Coagulation Medicine; Sahlgrenska University Hospital; Gothenburg Sweden

11. Department of Pathology; Lund University Hospital; Lund Sweden

12. Department of Genetics and Pathology; Uppsala University Hospital; Uppsala Sweden

13. Department of Pathology; Oslo University Hospital; Oslo Norway

14. Department of Pathology; Helsinki University Central Hospital; Helsinki Finland

15. Department of Systems Biology; Technical University of Denmark; Lyngby Denmark

16. Department of Health Sciences; University of Copenhagen; Copenhagen Denmark

Funder

Kraeftens Bekaempelse

The Nordic Cancer Union

The Novo Nordisk Foundation

The John and Birthe Meyer Foundation

Roche

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14241/fullpdf

Reference25 articles.

1. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study;Abrahamsson;Blood,2014

2. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma;Armand;British Journal of Haematology,2016

3. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213;Bernstein;Annals of Oncology,2013

4. Revised response criteria for malignant lymphoma;Cheson;Journal of Clinical Oncology,2007

5. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center;Chihara;British Journal of Haematology,2015

Cited by 166 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival Outcomes of Patients with Mantle Cell Lymphoma: A Retrospective, 15-Year, Real-Life Study;Hematology Reports;2024-01-18

2. Genetic and prognostic analysis of blastoid and pleomorphic mantle cell lymphoma: a multicenter analysis in China;Annals of Hematology;2024-01-02

3. Recent advances in genomics and therapeutics in mantle cell lymphoma;Cancer Treatment Reviews;2024-01

4. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma - a randomized, open-label phase III trial of the European mantle cell lymphoma network;2023-12-28

5. Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline;British Journal of Haematology;2023-10-25